# Optimal Dose of Acetylsalicylic Acid After Coronary Artery Bypass Grafting

> **NCT02482857** · PHASE2,PHASE3 · COMPLETED · sponsor: **Karolinska University Hospital** · enrollment: 45 (actual)

## Conditions studied

- Coronary Artery Bypass Surgery
- Stable Angina

## Interventions

- **DRUG:** Acetylsalicylic acid

## Key facts

- **NCT ID:** NCT02482857
- **Lead sponsor:** Karolinska University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2018-03-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02482857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02482857, "Optimal Dose of Acetylsalicylic Acid After Coronary Artery Bypass Grafting". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02482857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*